Related Experiment Videos

Adverse event reporting in clinical trials in Parkinson's Disease: Time for change

C Warren Olanow^1,2, Christopher Kenney³, Stephen Bandak³

¹Department of Neurology and Neuroscience, Mount Sinai School of Medicine, New York, New York, USA.

Movement Disorders : Official Journal of the Movement Disorder Society

|November 2, 2018

Abstract

No abstract available in PubMed .

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

Predicting CSF α-Synuclein Seed Amplification Assay Status From Demographics and Clinical Data.

Neurology open access·2026

A double-blind, controlled trial of circadian effective light therapy in patients with Parkinson's disease.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics·2025

Azetukalner, a Novel KV7 Potassium Channel Opener, in Adults With Major Depressive Disorder: A Randomized Clinical Trial.

JAMA network open·2025

Interim analysis of the long-term efficacy and safety of azetukalner in an ongoing open-label extension study following a phase 2b clinical trial (X-TOLE) in adults with focal epilepsy.

Epilepsia open·2025

CVN424, a GPR6 inverse agonist, for Parkinson's disease and motor fluctuations: a double-blind, randomized, phase 2 trial.

EClinicalMedicine·2024

Implementing a robotic hepatopancreatobiliary program for new faculty: safety, feasibility and lessons learned.

Journal of robotic surgery·2024

See all related articles